Well, there is a reference to the pain of the test itself, presumably the PSA (Prostate Specific Antigen) test.
Men who get tested for prostate specific antigen, or PSA, have a 13.5% chance of landing in the danger zone.
In the last few years, there has been some pushback against the potential over-use (and detriment) of mammograms and prostate specific antigen tests.
In addition, 54% of MDV3100 patients compared to 1.5% of those on placebo had a greater than 50% reduction in a marker called prostate specific antigen an indicator of a positive response to the drug.
But UC David professor Michael Wilkes investigated and learned that the seminar was primarily a sales pitch about the prostate specific antigen (PSA) test, and that its main message was that men should get tested regularly beginning at age 40.
FORBES: UC Davis threatens professor for writing about PSA testing
In May 2012, the U.S. Preventive Services Task Force recommended against routine PSA screening (Prostate-Specific Antigen test to screen Prostate cancer) before being diagnosed as it did not benefit patients.
FORBES: Intuitive Surgical Earnings Preview: What We Are Watching
Last month the task force advised against routine prostate-specific antigen (PSA) tests to screen for prostate cancer.
ECONOMIST: The philosophical error that plagues American health care
We began promoting and using the prostate-specific antigen test before it had been adequately evaluated.
Fortunately, earlier diagnosis of prostate cancer, thanks to prostate-specific antigen (PSA) testing, may have slowed and even reversed these trends, according to the study, which was published in the Journal of the National Cancer Institute.
The biotechnology firm announced that a much-awaited study of its bone drug Xgeva (also known as denosumab, and sold for osteoporosis as Prolia) prevented prostate cancer from spreading to the bone in patient whose levels of prostate-specific antigen are rising.
FORBES: Amgen Drug Prevents Prostate Cancer From Spreading To Bone
应用推荐